Niagen Bioscience Inc (NAGE) News & EventsNAGENiagen Bioscience Inc

Rob Fried: Q3 Revenue $27.2M, Outlook for Growth in 2027

Reports Q revenue $27.2M, consensus $31.9M. "During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform," said Rob Fried, Chief Executive Officer. "We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond."

Company Expects E-commerce Revenue Growth of 5%-20% in 2026

The company states: "For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The Company expects the performance of the remainder of its consumer business to offset the growth of the e-commerce business. The ingredient business is expected to be lower than the prior year, primarily due to decreased volume from key ingredient partners due to competitive market dynamics, although additional ingredient partners were added in Q3 2026 and more are expected to be added in the near term. The Company is planning to introduce a lower-cost NR salt form, patented by Niagen Bioscience, which is expected to reduce cost of goods sold and strengthen the ingredient business. The Company expects Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027. The Company believes 2026 is an important year of strategic investment and continues to expect operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations."

Niagen Bioscience Launches Prescription-Only Injection Kit

Niagen Bioscience announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen At-Home Injection Kit, featuring the Company's first ready-to-inject liquid formulation with Niagen, the most studied, high-quality NAD+ precursor brand available, now available through its Niagen Plus telehealth platform. Each kit includes a sterile, multi-dose 5 mL vial with 500 mg of Niagen, syringes, and alcohol prep pads. Patients simply draw the clinician-prescribed dose and inject subcutaneously: fewer components, fewer steps. The program remains clinician-directed and prescription-only. Patients complete an online intake form, a licensed provider decides whether to prescribe, and if prescribed, the medication is dispensed from state-licensed 503A compounding pharmacies and shipped to their door. NiagenPlus.com is LegitScript Certified, an independent third-party certification for healthcare merchants and telehealth platforms.